These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 14947014)

  • 1. MYXOMATOSIS and rabbits.
    Lancet; 1952 Aug; 2(6728):278-9. PubMed ID: 14947014
    [No Abstract]   [Full Text] [Related]  

  • 2. Virulence and pathogenesis of the MSW and MSD strains of Californian myxoma virus in European rabbits with genetic resistance to myxomatosis compared to rabbits with no genetic resistance.
    Silvers L; Inglis B; Labudovic A; Janssens PA; van Leeuwen BH; Kerr PJ
    Virology; 2006 Apr; 348(1):72-83. PubMed ID: 16442580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of rabbit IL-4 by recombinant myxoma viruses enhances virulence and overcomes genetic resistance to myxomatosis.
    Kerr PJ; Perkins HD; Inglis B; Stagg R; McLaughlin E; Collins SV; Van Leeuwen BH
    Virology; 2004 Jun; 324(1):117-28. PubMed ID: 15183059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transforming growth factor alpha, Shope fibroma growth factor, and vaccinia growth factor can replace myxoma growth factor in the induction of myxomatosis in rabbits.
    Opgenorth A; Nation N; Graham K; McFadden G
    Virology; 1993 Feb; 192(2):701-9. PubMed ID: 8380671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myxoma virus M-T7, a secreted homolog of the interferon-gamma receptor, is a critical virulence factor for the development of myxomatosis in European rabbits.
    Mossman K; Nation P; Macen J; Garbutt M; Lucas A; McFadden G
    Virology; 1996 Jan; 215(1):17-30. PubMed ID: 8553583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterization of SG33 and Borghi vaccines used against myxomatosis.
    Cavadini P; Botti G; Barbieri I; Lavazza A; Capucci L
    Vaccine; 2010 Jul; 28(33):5414-20. PubMed ID: 20598407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Epizootic of myxomatosis in rabbits (Sanarelli myxoma) in France].
    RAMON G
    Concours Med; 1953 Oct; 75(41):3339-43. PubMed ID: 13094889
    [No Abstract]   [Full Text] [Related]  

  • 8. MYXOMATOSIS in rabbits in Great Britain.
    Nature; 1954 May; 173(4410):856. PubMed ID: 13165666
    [No Abstract]   [Full Text] [Related]  

  • 9. MYXOMATOSIS.
    Med J Aust; 1951 Oct; 2(15):508. PubMed ID: 14890188
    [No Abstract]   [Full Text] [Related]  

  • 10. Myxomatosis in Australia and Europe: a model for emerging infectious diseases.
    Kerr PJ
    Antiviral Res; 2012 Mar; 93(3):387-415. PubMed ID: 22333483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental infection of specific pathogen-free New Zealand White rabbits with five strains of amyxomatous myxoma virus.
    Marlier D; Cassart D; Boucraut-Baralon C; Coignoul F; Vindevogel H
    J Comp Pathol; 1999 Nov; 121(4):369-84. PubMed ID: 10542126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune responses to myxoma virus.
    Kerr P; McFadden G
    Viral Immunol; 2002; 15(2):229-46. PubMed ID: 12081009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myxomatosis as a method of biological control against the Australian rabbit.
    BURNET FM
    Am J Public Health Nations Health; 1952 Dec; 42(12):1522-6. PubMed ID: 13007863
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of myxomatosis of rabbits with some antibiotics].
    JACOTOT H; VALLEE A; VIRAT B
    Ann Inst Pasteur (Paris); 1953 Dec; 85(6):801-3. PubMed ID: 13148822
    [No Abstract]   [Full Text] [Related]  

  • 15. Novel bivalent vectored vaccine for control of myxomatosis and rabbit haemorrhagic disease.
    Spibey N; McCabe VJ; Greenwood NM; Jack SC; Sutton D; van der Waart L
    Vet Rec; 2012 Mar; 170(12):309. PubMed ID: 22266680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coevolution of host and virus: cellular localization of virus in myxoma virus infection of resistant and susceptible European rabbits.
    Best SM; Collins SV; Kerr PJ
    Virology; 2000 Nov; 277(1):76-91. PubMed ID: 11062038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Administration of vaccine against myxomatosis using live MXT by means of external ear puncture with a special needle].
    Cupera Z; Krupka V; Jiran E
    Vet Med (Praha); 1982; 27(10):617-26. PubMed ID: 6815860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myxoma virus M130R is a novel virulence factor required for lethal myxomatosis in rabbits.
    Barrett JW; Werden SJ; Wang F; McKillop WM; Jimenez J; Villeneuve D; McFadden G; Dekaban GA
    Virus Res; 2009 Sep; 144(1-2):258-65. PubMed ID: 19477207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination of free-living juvenile wild rabbits (Oryctolagus cuniculus) against myxomatosis improved their survival.
    Guitton JS; Devillard S; Guénézan M; Fouchet D; Pontier D; Marchandeau S
    Prev Vet Med; 2008 Apr; 84(1-2):1-10. PubMed ID: 18045714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the myxoma virus soluble CC-chemokine inhibitor glycoprotein, M-T1, during myxoma virus pathogenesis.
    Lalani AS; Masters J; Graham K; Liu L; Lucas A; McFadden G
    Virology; 1999 Apr; 256(2):233-45. PubMed ID: 10191189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.